Vaxcyte (PCVX) Earnings Dates, Call Summary & Reports

Compare

458 Followers

Earnings Data

Report Date

May 11, 2026

After Close (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

-1.74

Last Year’s EPS

-1.04

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 7 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 24, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presents a strongly positive operational and clinical momentum story: robust balance sheet extended by a ~$600M financing, completion of a commercial-scale manufacturing facility on time and on budget, initiation of three pivotal/Phase III adult OPUS trials with expected top-line readouts over the next 18 months, completed infant enrollment (900 infants), and resumption of the Group A Strep program. Offsetting risks are mostly predictable near-term impacts from materially higher R&D and manufacturing expenses in 2026, serotype-level regulatory uncertainties (and the idiosyncratic challenge of serotype 3), and a competitive landscape with other PCV developers. Overall, the highlights—particularly cash runway, manufacturing completion, and late-stage clinical progress—materially outweigh the lowlights, which are manageable programmatic and financial execution risks.

Company Guidance

The company guided to a busy, capital-intensive 2026–2027 cadence: as of 12/31/2025 Vaxcyte had $2.4 billion in cash, then raised ~ $600.2 million net proceeds and said this funding provides runway to at least the end of 2028; it expects total expenses—particularly R&D—to increase meaningfully in 2026 while capitalized costs trend down. Key clinical and timing metrics: the OPUS Phase III program will enroll ~6,000 adults (≈3,400 receiving VAX‑31) with OPUS‑1 top‑line safety/tolerability/immunogenicity data expected in Q4 2026 and OPUS‑2 and OPUS‑3 readouts in H1 2027; the VAX‑31 infant Phase II optimized cohort enrollment is complete (900 infants dosed) with primary 3‑dose and booster data due by end H1 2027; VAX‑A1 Phase I in adults is planned to start in 2026. Product and regulatory metrics highlighted include a 31‑valent design with 10–11 incremental serotypes versus comparators, analytical plans that allow noninferiority against one comparator for the 10 shared serotypes, roughly 10 serotypes comparing head‑to‑head with Prevnar‑20 and 8 exclusive serotypes versus Capvaxive, and the expectation to meet conventional safety exposure norms (>3,000 subjects); manufacturing progress includes a dedicated large‑scale facility completed on time/on budget, a North Carolina fill‑finish build‑out as part of up to $1 billion U.S. manufacturing investment, and ongoing plans for a manufacturing consistency study.

Strong Financial Position and Recent Financing

Cash, cash equivalents and investments of $2.4 billion as of Dec 31, 2025, plus a subsequent public equity offering raising approximately $600.2 million in net proceeds; company states cash runway to at least the end of 2028.

Late-Stage Clinical Momentum — OPUS Phase III Program Initiated

Initiated OPUS-1 (pivotal noninferiority) in December, OPUS-2 (concomitant with seasonal influenza vaccine) in January, and OPUS-3 this month; the three OPUS trials will enroll ~6,000 adults total with ~3,400 receiving VAX-31; top-line OPUS-1 safety/tolerability/immunogenicity data expected in Q4 2026, OPUS-2/3 readouts expected in H1 2027.

Positive Phase II Immunogenicity Signals in Adults

Company cites 'unprecedented' Phase II adult results for VAX-31 versus Prevnar 20: directionally higher responses across common serotypes (18 of 20 directionally higher in Phase II) with 7 of 20 statistically significantly higher in Phase II, and 10–11 incremental serotypes over comparators.

Infant Program Enrollment Complete and Broad Pediatric Coverage

VAX-31 infant Phase II modified to include an optimized higher-dose arm; enrollment complete with 900 infants dosed. Company claims VAX-31 is designed to cover over 90% of invasive pneumococcal disease (IPD) and acute otitis media in U.S. children and states coverage of ~95%–98% of circulating disease in the U.S. and Europe, respectively.

Manufacturing and Commercial Readiness Achievements

Completed construction of a dedicated large-scale manufacturing facility on time and on budget; initiated build-out of a high-volume custom fill-finish production line in North Carolina as part of up to $1 billion long-term U.S. manufacturing and services investment; began scaling commercial organization including hiring first Chief Commercial Officer and launching launch planning activities.

Pipeline Re‑acceleration — VAX-A1 (Group A Strep) Resumed

After a prior pause, company plans to initiate a Phase I adult trial of VAX-A1 in 2026 focused on safety, tolerability and immunogenicity (serum and saliva IgG/IgA); program targeting Australia for early proof-of-concept given local disease burden.

Regulatory Engagement and Program Design Aligned with FDA

Pivotal Phase III program and supporting studies were designed in consultation with the FDA; company notes FDA feedback allowing limited serotype misses in totality-based licensure assessments and alignment around post-marketing surveillance approaches consistent with prior PCV approvals.

Vaxcyte (PCVX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PCVX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 11, 2026	2026 (Q1)	-1.74 / -	-1.04	―	―	―
Feb 24, 2026	2025 (Q4)	-1.53 / -1.81	-1.02	-77.45% (-0.79)	―
Nov 04, 2025	2025 (Q3)	-1.24 / -1.56	-0.83	-87.95% (-0.73)	―	―
Aug 06, 2025	2025 (Q2)	-1.16 / -1.22	-1.1	-10.91% (-0.12)	―	―
May 07, 2025	2025 (Q1)	-1.06 / -1.04	-0.85	-22.35% (-0.19)	―	―
Feb 25, 2025	2024 (Q4)	-1.11 / -1.02	-1.83	44.26% (+0.81)
Nov 05, 2024	2024 (Q3)	-1.10 / -0.83	-0.91	8.79% (+0.08)	―	―
Aug 06, 2024	2024 (Q2)	-0.98 / -1.10	-0.7	-57.14% (-0.40)	―	―
May 08, 2024	2024 (Q1)	-1.13 / -0.85	-0.7	-21.43% (-0.15)	―	―
Feb 27, 2024	2023 (Q4)	-1.05 / -1.83	-1.03	-77.67% (-0.80)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PCVX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 24, 2026	$61.35	$63.04	+2.75%
Nov 04, 2025	$41.35	$40.32	-2.49%
Aug 06, 2025	$33.00	$30.01	-9.06%
May 07, 2025	$29.00	$31.45	+8.45%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vaxcyte, Inc. (PCVX) report earnings?

Vaxcyte, Inc. (PCVX) is schdueled to report earning on May 11, 2026, After Close (Confirmed).

What is Vaxcyte, Inc. (PCVX) earnings time?

Vaxcyte, Inc. (PCVX) earnings time is at May 11, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PCVX EPS forecast?

PCVX EPS forecast for the fiscal quarter 2026 (Q1) is -1.74.